Sorry, you need to enable JavaScript to visit this website.

INDICATION & USAGE: MONJUVI 
(tafasitamab-cxix), in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

rays mobile rays desktop

LONG-TERM DATA 
FOR SECOND LINE+

MONJUVI is the only outpatient targeted immunotherapy for adult NTE patients with R/R DLBCL in 2L with 5-year data.1,2*

MONJUVI (tafasitamab-cxix), in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

The 5-year analysis data from L-MIND have not been submitted to or reviewed by the FDA, and potential inclusion of these data in the final FDA-approved labeling has yet to be determined.

*MONJUVI is a CD19-directed cytolytic monoclonal antibody.1

*MONJUVI is a CD19-directed cytolytic monoclonal antibody.1

2L Treatment Factors

Uncover factors that drive 
2L treatment decisions

Learn more
MONJUVI Efficacy

Explore the L-MIND 
clinical study results

See the data
Safety

Review the well-established  
safety profile of MONJUVI1,2

Explore